Quantcast

Latest Cancer immunotherapy Stories

2013-06-03 12:37:18

The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO). Several patients...

2013-06-02 23:01:05

A promising, new cancer immunotherapy combination treatment showing long term survival for patients with metastatic melanoma was highlighted today at the American Society of Clinical Oncology Annual Meeting in Chicago. (PRWEB) June 02, 2013 A promising, new cancer immunotherapy combination treatment showing long term survival for patients with metastatic melanoma was highlighted today at the American Society of Clinical Oncology Annual Meeting in Chicago. Results form a phase II study...

2013-06-02 23:00:29

Additional Data Released at ASCO Annual Meeting Shows More Promising Results for Immunotherapy as a Treatment Option in Melanoma Chicago, IL (PRWEB) June 02, 2013 Some of the most promising results ever seen in melanoma clinical trials were announced today at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The drugs work by manipulating the immune system to increase anti-tumor immunity. Specifically, they target the program death-1 (PD-1) receptor pathway which...

2013-05-30 23:14:29

FDA Review in SITC's Journal for ImmunoTherapy of Cancer offers new insights into cancer immunotherapy product development & clinical evaluation. Milwaukee, WI (PRWEB) May 30, 2013 A picture of what the FDA is looking for in cancer immunotherapy product development appears in an extensive new review article published in the inaugural issue of the Journal for ImmunoTherapy of Cancer. Providing a US regulatory perspective on pre-clinical to first in man studies, the review is described...

2013-05-27 10:43:58

Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ignore cancer cells. Regulatory T cells are immune cells that function to suppress the immune system response. In this issue of the Journal of Clinical Investigation, researchers led by Ronald Levy at Stanford University found that regulatory T cells that infiltrate tumors...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related